Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Dermatol Venereol Leprol. 2010 Nov-Dec;76(6):645-51. doi: 10.4103/0378-6323.72457.
Psoriatic arthritis (PsA) is a chronic inflammatory disease that can be progressive and may be associated with permanent joint damage and disability. Early identification of PsA will enable these patients with progressive disease to be treated early and aggressively. Due to lack of consistent diagnostic or classification criteria in the past, PsA was considered as uncommon. Overall it affects 6-10% of all psoriasis patients during the course of their disease. Both dermatologists and rheumatologists should be involved in the diagnosis and management of this disorder. Interest in PsA has greatly enhanced over the past several years due to many factors including a better understanding of disease mechanisms, improved investigational tools, better clinical trial design and perhaps most importantly, the availability of newer therapeutic agents. Mild forms of PsA can initially be treated with nonsteroidal antiinflammatory drugs (NSAID). In acute as well as oligo- to polyarticular joint involvement, disease-modifying anti-rheumatic drugs (DMARD) are indicated for PsA. The biologics particularly tumor necrosis factor alpha (TNF-α) antagonists are gaining increasing significance as second-line therapy. Treatment choice should also take into consideration the extent of skin involvement.
银屑病关节炎（PsA）是一种慢性炎症性疾病，具有进展性，可能导致永久性关节损伤和残疾。早期识别出患有进展性疾病的银屑病关节炎患者，可使他们得到早期和积极的治疗。由于过去缺乏一致的诊断或分类标准，银屑病关节炎被认为不太常见。总体而言，在疾病过程中，它影响所有银屑病患者的 6-10%。皮肤科医生和风湿病医生都应参与这种疾病的诊断和管理。由于多种因素，包括对疾病机制的更好理解、改进的研究工具、更好的临床试验设计，以及也许最重要的是新型治疗药物的出现，近年来人们对银屑病关节炎的兴趣大大增强。轻度银屑病关节炎最初可以用非甾体抗炎药（NSAID）治疗。在急性和少关节至多关节受累的情况下，需要使用疾病修饰抗风湿药物（DMARD）治疗银屑病关节炎。生物制剂，特别是肿瘤坏死因子-α（TNF-α）拮抗剂，作为二线治疗药物的地位日益重要。治疗选择还应考虑皮肤受累的程度。
